🎙 This week, discover a new episode dedicated to the patentability of psychedelics.

Recorded on the sidelines of the AIPPI 2025 Midterm Meeting in Zagreb, this episode explores how long-known compounds are returning to the spotlight and what that means for patents, regulation, and access.

💬 We discuss with:

· Charles Boulakia, Vice Chair of the AIPPI Pharma Committee, Chair of the Patent Committee (AIPPI Canada), Patent Lawyer and Patent Agent at Smart & Biggar (Canada)

· Pablo Fuentes Barrón, Member of the AIPPI Pharma Committee, Patent Attorney at BREAKTHROUGH IP INTELLIGENCE (Mexico)

· Takeshi S. Komatani Ph.D., LL.D., LL.M, Vice Chair of the AIPPI Committee on the TRIPS Agreement, Patent Attorney at Takashima International Patent Office (Japan)

· Julie Dagher, Research assistant and PhD candidate at CEIPI

Topics:

- What challenges arise when trying to get a patent from a compound that comes from nature?

- How do regulatory and legal frameworks differ for psychedelics compared to traditional pharmaceuticals?

- What concrete cases of psychedelic-related patents have been filled in different jurisdictions, and what filing strategies were used?

- How to ensure balance between patent protection and equitable access to treatment?

This episode is sponsored by PAPERZ IP - Camille Champion

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.